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Background: Low circulating levels of total vitamin D [25(OH)D] and 25(OH)D3 have been associated with vascular
complications in few studies on individuals with type 1 diabetes. However, these measures are affected by UV light
exposure. Circulating 25(OH)D2, however, solely represents dietary intake of vitamin D2, but its association with
complications of diabetes is currently unknown. We investigated the associations between 25(OH)D2 and 25(OH)D3
and the prevalence of albuminuria, retinopathy and cardiovascular disease (CVD) in individuals with type 1 diabetes.
Methods: We measured circulating 25(OH)D2 and 25(OH)D3 in 532 individuals (40 ± 10 years old, 51 % men) with type 1
diabetes who participated in the EURODIAB Prospective Complications Study. Cross-sectional associations of 25(OH)D2
and 25(OH)D3 with albuminuria, retinopathy and CVD were assessed with multiple logistic regression analyses adjusted
for age, sex, season, BMI, smoking, HbA1c, total-HDL-cholesterol-ratio, systolic blood pressure, antihypertensive medication,
eGFR, physical activity, alcohol intake, albuminuria, retinopathy and CVD, as appropriate.
Results: Fully adjusted models revealed that 1 nmol/L higher 25(OH)D2 and 10 nmol/L higher 25(OH)D3 were associated
with lower prevalence of macroalbuminuria with ORs (95 % CI) of 0.56 (0.43;0.74) and 0.82 (0.72;0.94), respectively.
These vitamin D species were not independently associated with microalbuminuria, non-proliferative and proliferative
retinopathy or CVD.
Conclusions: In individuals with type 1 diabetes, both higher 25(OH)D2 and 25(OH)D3 are associated with a lower
prevalence of macroalbuminuria, but not of retinopathy and CVD. Prospective studies are needed to further examine
the associations between 25(OH)D2 and 25(OH)D3 and the development of microvascular complications and CVD in
type 1 diabetes.
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Vitamin D plays an important role in human health, in
particular in bone metabolism [1]. In addition, vitamin
D deficiency has been shown to be involved in several
pathophysiological processes, such as inflammation [2–4],
endothelial dysfunction [5, 6] and up-regulation of the
renin-angiotensin-aldosterone system (RAAS) [7], that have
been associated with the development of complications of
type 1 diabetes [8–10]. In line with this, few observational
cohort studies in individuals with type 1 diabetes have
shown associations between low 25-hydroxyvitamin D
[25(OH)D, which is the sum of 25(OH)D2 and 25(OH)D3]
[11, 12] and low 25(OH)D3 [13] on the one hand and
microvascular complications [11, 12] and mortality [13] on
the other.
Although 25(OH)D3 can be produced after consumption
of vitamin D3-containing foods such as meat, egg yolk and
fatty fish, vitamin D3-fortified foods and vitamin D3 supple-
ments, it is mainly produced when skin is exposed to UV
light [1]. As any disease state is likely to reduce physical
activity and thereby UV light exposure and 25(OH)D3
levels, reverse causality is an important limitation of ob-
servational studies on the associations between total
25(OH)D or 25(OH)D3 and disease [14]. In contrast,
circulating 25(OH)D2 is not directly influenced by ex-
posure to UV light and thus solely represents dietary in-
take of vitamin D2, mainly from shiitake mushrooms,
egg yolk and potentially other foods [1], vitamin D2-for-
tified foods and from vitamin D2 supplements [1, 15]. It
is therefore of interest to specifically investigate and
compare associations between the two 25(OH)D metabo-
lites – 25(OH)D2 and 25(OH)D3 – and vascular disease. So
far no studies have been published on the associations be-
tween circulating 25(OH)D2 and microvascular complica-
tions and cardiovascular disease (CVD) in individuals with
type 1 diabetes.
We therefore aimed to investigate the associations be-
tween both circulating 25(OH)D2 and 25(OH)D3 and the
prevalence of microalbuminuria, macroalbuminuria, and
non-proliferative and proliferative retinopathy and CVD
in a European cohort of individuals with type 1 diabetes.
Methods
Study population
We used data from the EURODIAB Prospective Com-
plications Study, a European based prospective cohort
study [16, 17]. In brief, baseline investigations were per-
formed between 1989 and 1991 on 3,250 patients with
type 1 diabetes, defined as clinical diagnosis made before
the age of 36, and needing continuous insulin therapy
within one year of diagnosis. Patients aged 15–60 years
were recruited from 31 centres in 16 European countries.
Sample selection was stratified by sex, age group and dur-
ation of diabetes to ensure sufficient representation in allcategories. These patients were invited for a follow-up
examination 7–9 years after the baseline examinations. Of
the 3,250 included patients, 1,880 (58 %) returned for re-
examination. At follow-up, a cross-sectional nested case–
control study of markers of inflammation and endothelial
dysfunction and their associations with complications was
performed in a subset of patients (n = 543). Cases were se-
lected as those with the greatest vascular complication
burden as possible (i.e., individuals with CVD or prolifera-
tive retinopathy or macroalbuminuria and individuals with
microalbuminuria and some degree of retinopathy, n =
348) and controls were selected as those who were com-
pletely free of any complications (i.e., with no evidence of
CVD, albuminuria and retinopathy; n = 195) [18]. The
present study includes 532 of these patients from the
cross-sectional case–control study at follow-up in
whom plasma samples were available for determination
of vitamin D.
Ethics committee approval conformed to the Declaration
of Helsinki was obtained at each centre and all participants
provided written informed consent.
Measurement of 25-hydroxyvitamin D2 and
25-hydroxyvitamin D3
Concentrations of 25(OH)D2 and 25(OH)D3 were deter-
mined with the use of ultra-performance liquid chromatog-
raphy (UPLC) tandem mass spectrometry (MS) in plasma
samples that were stored at −80 °C until analyses.
Two hundred μL plasma was mixed with 200 μL [d3]-
25(OH)D3 (50 nmol/L ethanol) and 20 μL perchloric acid
(50 %, v/v), 1600 μL hexane was added and samples were
centrifuged for 10 min at 14000 rpm at a temperature of
4 °C. The supernatant was dried under a stream of nitro-
gen and derivatised with 100 μL 4-phenyl-1,2,4-triazoline-
3,5-dione (PTAD, 0,1 mg/mL ethylacetate) for 30 min,
both at room temperature. Excess PTAD was removed
with 400 μL ethanol and the supernatant was then again
dried under a stream of nitrogen. The residue was dis-
solved in 50 μL acetonitrile and 5 μL was injected for ana-
lysis by UPLC (Acquity UPLC, Waters, Milford, USA) and
detection by tandem MS in ESI positive multiple reaction
monitoring (MRM) mode using a Xevo TQ MS (Waters,
Milford, USA). Derivatives were separated on a reversed-
phase C18 column (Acquity UPLC BEH C18, 100 x
2.1 mm, 1.7 μm) with a binary gradient of 5 mmol/L for-
mic acid and acetonitril at a flow rate of 500 μL/min. The
injection volume was 5 μL and column temperature was
set at 35 °C. Quantification of 25(OH)D2 and 25(OH)D3
was performed by calculating the peak area ratio of each
unlabeled peak area to the peak area of the internal
standard [d3]-25(OH)D3. The MRM transitions for
25(OH)D2 and 25(OH)D3 were 570.3 > 298.1 and 558.2 >
298.1, respectively. The MRM transitions for the internal
standard [d3]-25(OH)D3 was 561.2 > 301.1. Electrospray
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temperature of 150 °C and a desolvation temperature of
600 °C.
For validation purposes, linearity was determined by
adding standard solution of 25(OH)D2 and 25(OH)D3 to
water and plasma. A six-point calibration curve was
prepared for 25(OH)D2 (0–79.6 nmol/L) and 25(OH)D3
(0–16.2 nmol/L). The peak area ratio of 25(OH)D2 and
25(OH)D3 multiplied by the concentration of the in-
ternal standard were plotted as a function of the concentra-
tion. Calibration curves for 25(OH)D2 and 25(OH)D3 were
linear over the described ranges (r2 > 0.99) in both water
and plasma. Mean slopes (response factors) for 25(OH)D2
and 25(OH)D3 were 0.9594 [coefficient of variation (CV):
6.1 %] and 0.6212 (CV: 14.9 %), respectively. Inter- and
intra-assay CVs for concentrations of 25(OH)D2 were
4.6 % and 3.1 % and for concentrations of 25(OH)D2 were
8.9 % and 9.1 %, respectively.
Microvascular complications
The albumin excretion rate (AER) was measured from
duplicate 24-h urine collections using an immunoturbi-
dimetric method that included goat anti-human albumin
antisera (Sanofi Diagnostics Pasteur, Chaska, MN, USA)
and human serum albumin standards (ORHA 20/21
grade HSA; Behring Diagnostics, Hoechst UK, Houns-
low, UK) [19]. Microalbuminuria and macroalbuminuria
were defined as AER 20–200 μg/min and >200 μg/min,
respectively.
Retinopathy was centrally assessed from retinal photo-
graphs by a trained reader of colour retinal photographs
using a system of 45° field grading standards for the as-
sessment of retinopathy that was developed for the
EURODIAB Prospective Complications Study. Non-
proliferative retinopathy was defined as the presence of
one or more microaneurysms, haemorrhages and/or hard
exudates. Proliferative retinopathy was defined as any new
vessel, fibrous proliferation, pre-retinal haemorrhage, vit-
reous haemorrhage or photocoagulation scar [20].
Cardiovascular disease
CVD was defined as a positive medical history of a car-
diovascular event, including myocardial infarction, an-
gina pectoris, coronary artery bypass graft and/or stroke,
and/or ischaemic changes on a centrally Minnesota-coded
ECG [17].
Covariables
Weight and height were measured with indoor clothing
without shoes and body mass index (BMI) was calculated
as weight divided by height squared. Smoking habits were
ascertained by questionnaire and individuals were cate-
gorised into never smokers, ex-smokers and current
smokers. Glycated haemoglobin (HbA1c) was measured bya latex enhanced turbidimetric immunoassay. Cholesterol
levels were measured with colorimetric tests and HDL
cholesterol was measured directly. Blood pressure was re-
corded twice with a random zero sphygmomanometer
(Hawskley, Lancing, UK). The glomerular filtration rate
(GFR) was estimated using the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation [21].
Self-reported physical activity was assessed by a question-
naire [22]. The weekly metabolic equivalent (MET-h) cor-
responds to the weekly amount of time spent in each
sporting activity multiplied by the corresponding MET
value. Physical activity was then categorized into none,
low (≤sex-specific median) and high (>sex-specific me-
dian). Alcohol intake was assessed using the general
questionnaire and determined by multiplying the weekly
intake of each alcoholic beverage by its ethanol content
[23]. Alcohol intake was categorized into abstainers,
low (≤70 g/week) and high (>70 g/week). We measured
plasma levels of C-reactive protein (CRP) with a highly
sensitive in-house ELISA [24] and plasma levels of IL-6
and TNF-α with commercially available ELISA kits
(R&D Systems, Oxon, UK) [24], as markers of low-grade
inflammation. Soluble vascular cell adhesion molecule-1
(sVCAM-1) and soluble E-selectin (sE-selectin) were mea-
sured in duplicate by sandwich enzyme immunoassays
(R&D Systems, Oxon, UK), as markers of endothelial
dysfunction.
Statistical analyses
All statistical analyses were carried out using the Statis-
tical Package for the Social Sciences, version 20.0 (SPSS
IBM Corporation, Armonk, NY, USA), unless specified
otherwise. General characteristics were compared be-
tween tertiles of 25(OH)D2 and, to account for seasonal
variation due to UV light exposure, month-specific ter-
tiles of 25(OH)D3 with the use of ANOVA or χ
2 tests for
continuous and categorical data, respectively. Seven per-
cent (37 individuals) of the total population had missing
values for one (n = 30) or more (n = 7) of the covariates.
The percentage of missing values per variable varied
from 0.2 % (physical activity) to 2.6 % (TNF-α). We used
multiple imputation chained equations to impute those
missing values rather than perform complete case ana-
lyses in order to decrease bias and increase the power of
the analyses [25].
We used multinomial logistic regression analyses to
investigate the associations between 25(OH)D2 and
25(OH)D3 levels and the prevalence of microalbumi-
nuria and macroalbuminuria, and of non-proliferative
and proliferative retinopathy, respectively. Binary logis-
tic regression analyses were performed to investigate
the associations between 25(OH)D2 and 25(OH)D3
levels and the prevalence of CVD. All analyses were ad-
justed for age and sex [and, in the case of 25(OH)D3,
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BMI, smoking, HbA1c, total-HDL-cholesterol-ratio, sys-
tolic blood pressure, use of antihypertensive medication,
eGFR, physical activity, alcohol intake, and for prevalent
CVD, albuminuria and retinopathy, as appropriate
(model 2). We investigated these associations both with
25(OH)D2 tertiles and month-specific 25(OH)D3 ter-
tiles, and with 25(OH)D2 and 25(OH)D3 levels as con-
tinuous variables [additionally adjusting for season of
examination in the case of 25(OH)D3].
Decreased kidney function may impair the conversion
of 25(OH)D into its active form 1,25(OH)2D [1]. We
therefore tested for interaction with eGFR, on the multi-
plicative scale by adding product terms between eGFR
and 25(OH)D2 and 25(OH)D3 levels to the fully adjusted
models, and on the additive scale by calculating the rela-
tive excess risk due to interaction [26].
Lastly, linear regression analyses were conducted to
investigate the associations between 25(OH)D2 and
25(OH)D3 and markers of low-grade inflammation (both
individually and comprised in an averaged Z-score of CRP,
IL-6 and TNF-α) and endothelial function (both individu-
ally and comprised in an averaged Z-score of sVCAM-1
and sE-selectin-1) [27]. Furthermore, in the case of signifi-
cant associations between 25(OH)D2 and 25(OH)D3 and
vascular complications, we additionally adjusted these as-
sociations for the low-grade inflammation and endothelial
dysfunction scores to investigate to what extent these
pathophysiological processes explained (i.e., attenuated)
these associations.Fig. 1 Concentration of 25(OH)D2 (a) and 25(OH)D3 (b) according to
month of examination. Boxes indicate medians and interquartile
ranges and whiskers represent the minimum and maximum valuesResults
In the total population, median (IQR) plasma 25(OH)D2
and 25(OH)D3 concentrations were 1.5 (1.0-2.4) nmol/L
and 51 (33–74) nmol/L, respectively. Plasma levels of
25(OH)D2 and 25(OH)D3 were not correlated (rS = −0.04,
p = 0.363).
Figure 1 shows plasma levels of 25(OH)D2 and
25(OH)D3 across months of examination. Levels of
25(OH)D3, which are dependent on sunlight exposure,
differed according to season of examination, whereas
levels of 25(OH)D2 did not. We calculated month-specific
tertiles of 25(OH)D3 to account for the variation in
25(OH)D3 between seasons and used these in all further
analyses with tertiles of 25(OH)D3. Additional file 1:
Figure S1 (supplemental material) shows plasma levels
of 25(OH)D2 and 25(OH)D3 according to latitude of the
study centre. We found no evidence for decreasing levels
of 25(OH)D2 or 25(OH)D3 with increasing latitude.
Eighty-three and 124 individuals had microalbumi-
nuria and macroalbuminuria, respectively; 146 and 152
individuals had non-proliferative and proliferative retin-
opathy, respectively, and 131 individuals had CVD.Population characteristics
Table 1 shows the general characteristics of the EURO-
DIAB Prospective Complications Study population accord-
ing to tertiles of 25(OH)D2 and month-specific tertiles of
25(OH)D3.
Individuals with higher 25(OH)D2 and those with higher
month-specific 25(OH)D3 concentrations had on aver-
age lower values of total-HDL-cholesterol-ratio and
markers of low-grade inflammation and endothelial
dysfunction compared to those with lower vitamin D
concentrations. In addition, they less often used antihy-
pertensive medication and less often had albuminuria
and retinopathy.
Finally, those with higher 25(OH)D2 concentrations
had on average lower systolic blood pressure, but
higher eGFR, whereas individuals with higher month-
specific 25(OH)D3 were on average somewhat younger
and had lower HbA1c and duration of diabetes, but
higher physical activity and alcohol intake (Table 1).
Table 1 General characteristics of the study population (n = 532) according to tertiles of 25-hydroxyvitamin D2 and month-specific
tertiles of 25-hydroxyvitamin D3
25-hydroxyvitamin D2 25-hydroxyvitamin D3
T1 (n = 177,
0.08-1.19 nmol/L)
T2 (n = 178,
1.20-2.09 nmol/L)
T3 (n = 177,
2.10-20.2 nmol/L)
T1 (n = 177,
8–86 nmol/L)d




Age (years) 40.5 ± 10.5 39.0 ± 9.8 39.2 ± 10.0 40.9 ± 10.4 39.5 ± 10.3 38.2 ± 9.4
Male sex (%) 51 47 55 53 52 49
Body mass index (kg/m2) 24.5 ± 3.4 24.7 ± 3.1 24.3 ± 3.3 24.7 ± 3.7 24.5 ± 3.1 24.2 ± 2.8
HbA1c (%) (mmol/mol) 8.7 ± 1.7 (72 ± 19) 8.5 ± 1.7 (69 ± 19) 8.5 ± 1.5 (69 ± 16) 9.0 ± 1.8 (75 ± 20) 8.4 ± 1.5 (68 ± 16) 8.2 ± 1.5 (66 ± 16)
Duration of diabetes (years) 22.9 ± 9.0 20.5 ± 9.7 20.9 ± 9.3 22.8 ± 9.2 22.2 ± 9.9 19.4 ± 8.8
Total cholesterol (mmol/L) 5.4 ± 1.4 5.4 ± 1.1 5.1 ± 1.1 5.4 ± 1.3 5.2 ± 1.1 5.3 ± 1.2
LDL cholesterol (mmol/L) 3.2 ± 1.2 3.1 ± 1.0 3.2 ± 1.0 3.2 ± 1.1 3.1 ± 1.0 3.2 ± 1.1
HDL cholesterol (mmol/L) 1.6 ± 0.5 1.6 ± 0.4 1.6 ± 0.4 1.6 ± 0.4 1.6 ± 0.4 1.7 ± 0.4
Total-HDL-cholesterol-ratio 3.7 ± 1.3 3.5 ± 1.4 3.3 ± 1.0 3.7 ± 1.5 3.4 ± 1.1 3.3 ± 1.1
Triacylglycerols (mmol/L) 1.0 (0.8-1.4) 1.0 (0.7-1.4) 0.9 (0.7-1.2) 1.0 (0.7-1.5) 1.0 (0.8-1.4) 0.9 (0.7-1.2)
Smoking (never/ex/current, %) 39/32/29 39/32/29 42/24/34 37/28/35 42/30/28 41/30/29
Physical activity
(0/≤mediana/>median, %)
68/17/15 59/20/21 60/21/19 74/14/12 63/20/17 50/25/25
Alcohol intake
(0/≤70 g per wk/>70 g per wk, %)
16/53/31 19/53/28 10/57/33 21/53/26 13/56/31 10/55/35
Systolic blood pressure (mmHg) 127 ± 22 121 ± 19 120 ± 18 125 ± 21 121 ± 20 123 ± 18
Diastolic blood pressure (mmHg) 76 ± 11 75 ± 12 74 ± 11 76 ± 12 73 ± 11 76 ± 11
Use of antihypertensive
medication (%)
45 31 19 36 33 26
Use of hormone replacement therapy
(% women)
14 11 10 11 8 15
Use of oral contraceptive therapy
(% women)
39 42 47 27 49 50
Estimated glomerular filtration rate
(mL/min)
97 (77–109) 103 (88–114) 104 (91–113) 102 (82–112) 102 (86–112) 101 (89–112)
C-reactive protein (mg/L) 1.1 (0.5-2.7) 1.0 (0.4-2.5) 1.1 (0.4-2.4) 1.4 (0.5-3.5) 0.9 (0.4-2.3) 0.9 (0.4-2.4)
Interleukin-6 (pg/mL) 2.1 (1.5-4.0) 1.8 (1.1-3.0) 1.8 (1.2-3.1) 2.3 (1.5-4.4) 1.9 (1.2-3.0) 1.6 (1.1-2.8)
Tumour necrosis factor-α (pg/mL) 3.2 (2.3-4.6) 2.7 (2.0-3.3) 2.6 (2.0-3.2) 3.1 (2.2-4.3) 2.7 (2.1-3.5) 2.7 (2.1-3.4)
Low-grade inflammation score (SD)b 0.27 ± 1.00 −0.13 ± 0.99 −0.14 ± 0.97 0.26 ± 1.10 −0.11 ± 0.87 −0.14 ± 0.97
Soluble E-selectin (ng/mL) 36 ± 20 32 ± 11 35 ± 12 36 ± 16 35 ± 16 32 ± 13
Soluble vascular cell adhesion
molecule-1 (ng/mL)
451 ± 174 391 ± 97 387 ± 98 438 ± 169 399 ± 106 393 ± 103
Endothelial dysfunction score (SD)c 0.30 ± 1.32 −0.22 ± 0.74 −0.08 ± 0.76 0.21 ± 1.15 −0.04 ± 0.97 −0.17 ± 0.82
Albuminuria (normo/micro/macro, %) 45/13/42 65/17/18 73/17/10 52/14/34 58/20/22 74/13/13
Retinopathy (none/non-proliferative/
proliferative, %)
34/30/36 49/27/24 49/25/26 34/33/33 44/28/28 54/21/25
Cardiovascular disease (%) 21 29 24 28 27 20
25-hydroxyvitamin D2 (nmol/L) 0.8 (0.6-1.0) 1.5 (1.4-1.8) 2.8 (2.4-3.9) 1.4 (0.9-2.5) 1.6 (1.1-2.4) 1.6 (1.1-2.4)
25-hydroxyvitamin D3 (nmol/L) 46 (28–73) 58 (37–75) 49 (33–74) 27 (21–38) 48 (39–67) 77 (62–98)
Data are presented as means ± SD, medians (interquartile range) or percentages, as appropriate. asex-specific medians for physical activity were 11.3 MET-h/week
for men and 6.8 MET-h/week for women; bthe low-grade inflammation score was calculated as the mean Z-score of ln-transformed values of C-reactive protein,
interleukin-6 and tumour necrosis factor-α; cthe endothelial dysfunction score was calculated as the mean Z-score of soluble E-selectin and soluble vascular cell
adhesion molecule-1; dranges of 25-hydroxyvitamin D3 concentrations overlap between tertiles as tertiles were defined month-specifically (see Methods section)
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Table 3 Associations between 25-hydroxyvitamin D3 levels and
prevalent albuminuria, retinopathy and CVD
25-hydroxyvitamin D3 per 10 nmol/L
Model OR 95 % CI p
Microalbuminuria
(n = 83)
1 0.93 0.84; 1.03 0.17
2 0.93 0.83; 1.05 0.26
3 0.94 0.83; 1.06 0.30
4 0.94 0.83; 1.06 0.30
Macroalbuminuria
(n = 124)
1 0.80 0.72; 0.88 <0.001
2 0.82 0.72; 0.94 0.003
3 0.82 0.72; 0.94 0.005
4 0.82 0.72; 0.94 0.005
Non-proliferative retinopathy
(n= 146)
1 0.90 0.82; 0.99 0.022
2 0.98 0.87; 1.09 0.66
Proliferative retinopathy
(n = 152)
1 0.90 0.83; 0.98 0.018
2 1.01 0.90; 1.13 0.87
CVD (n = 131) 1 0.99 0.91; 1.08 0.84
2 1.02 0.93; 1.12 0.66
OR, odds ratio indicates the odds of prevalent albuminuria, retinopathy and
CVD per 10 nmol/L higher 25-hydroxyvitamin D3. Model 1: adjusted for age,
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Fully adjusted continuous analyses showed that 1 nmol/L
higher 25(OH)D2 was non-significantly associated with
lower prevalence of microalbuminuria, with an OR (95 %
CI) of 0.85 (0.70;1.04), and significantly with macroalbumi-
nuria [0.56 (0.43;0.74)]. Associations between 25(OH)D2
and non-proliferative retinopathy [1.00 (0.85;1.16)], pro-
liferative retinopathy [1.08 (0.93;1.25)] and CVD [1.03
(0.90;1.16)] were not significant (Table 2, model 2). Associa-
tions between tertiles of 25(OH)D2 and microvascular com-
plications showed comparable results. However, comparing
tertile 2 (T2) vs. T1 of 25(OH)D2, 25(OH)D2 was associated
with higher prevalence of CVD [2.22 (1.23;4.01)], whereas
T3 vs. T1 was not [1.64 (0.89;3.05)] (Additional file 1: Table
S1, model 2).
Associations between 25-hydroxyvitamin D3 and
albuminuria, retinopathy and cardiovascular disease
Fully adjusted continuous analyses showed that 10 nmol/L
higher 25(OH)D3 was associated with lower prevalence of
macroalbuminuria [0.82 (0.72;0.94)], but not with microal-
buminuria [0.93 (0.83;1.05)], non-proliferative retinopathy
[0.98 (0.87;1.09)], proliferative retinopathy [1.01 (0.90;1.13)]
and CVD [1.02 (0.93;1.12)] (Table 3, model 2). AssociationsTable 2 Associations between 25-hydroxyvitamin D2 levels and
prevalent albuminuria, retinopathy and cardiovascular disease
25-hydroxyvitamin D2 per 1 nmol/L
Model OR 95 % CI p
Microalbuminuria (n = 83) 1 0.94 0.81; 1.09 0.42
2 0.85 0.70; 1.04 0.11
3 0.86 0.71; 1.05 0.14
4 0.85 0.70; 1.03 0.09
Macroalbuminuria (n = 124) 1 0.45 0.35; 0.60 <0.001
2 0.56 0.43; 0.74 <0.001
3 0.57 0.43; 0.75 <0.001
4 0.56 0.42; 0.74 <0.001
Non-proliferative retinopathy
(n = 146)
1 0.91 0.80; 1.03 0.15
2 1.00 0.85; 1.16 0.95
Proliferative retinopathy
(n = 152)
1 0.88 0.77; 1.00 0.06
2 1.08 0.93; 1.25 0.33
CVD (n = 131) 1 1.02 0.92; 1.14 0.70
2 1.03 0.90; 1.16 0.70
OR, odds ratio indicates the odds of prevalent albuminuria, retinopathy and
CVD, per 1 nmol/L higher 25-hydroxyvitamin D2. Model 1: adjusted for age
and sex; Model 2: model 1 + BMI, smoking (never, ex, current), HbA1c, total-HDL-
cholesterol-ratio, systolic blood pressure, use of antihypertensive medication,
eGFR, physical activity (0, ≤sex-specific median, >sex-specific median), alcohol intake
(0, ≤70 g/wk, >70 g/wk), and prevalent CVD, albuminuria and retinopathy, as
appropriate; Model 3: model 2 + low-grade inflammation score; Model 4:
model 2 + endothelial dysfunction score
sex and season; Model 2: model 1 + BMI, smoking (never, ex, current), HbA1c,
total-HDL-cholesterol-ratio, systolic blood pressure, use of antihypertensive
medication, eGFR, physical activity (0, ≤sex-specific median, >sex-specific
median), alcohol intake (0, ≤70 g/wk, >70 g/wk), and prevalent albuminuria,
retinopathy and CVD, as appropriate; Model 3: model 2 + low-grade inflammation
score; Model 4: model 2 + endothelial dysfunction scorebetween month-specific tertiles of 25(OH)D3 and micro-
vascular complications and CVD showed comparable re-
sults (Additional file 1: Table S2, model 2).Additional analyses
Additional adjustment for hormone replacement therapy
and/or oral contraceptive therapy did not materially change
the results (data not shown).
We found no consistent significant additive or multiplica-
tive interactions between 25(OH)D2 or 25(OH)D3 and
eGFR in the associations with microvascular complications
and CVD (data not shown).
Additional file 1: Table S3 and S4 show the associa-
tions between 25(OH)D2 and 25(OH)D3 levels, re-
spectively, and markers of low-grade inflammation
and endothelial dysfunction.
Fully adjusted continuous analyses showed that 1 nmol/L
higher 25(OH)D2 was not significantly associated with
lower scores of low-grade inflammation and endothelial
dysfunction. However, comparing T2 vs. T1 of 25(OH)D2
[−0.239 SD (−0.420;-0.058)] as well as T3 vs. T1 [−0.190
(−0.371;-0.009)], 25(OH)D2 was associated with lower
Engelen et al. Cardiovascular Diabetology  (2015) 14:67 Page 7 of 9low-grade inflammation. In addition, both 25(OH)D2 T2
vs. T1 [−0.363 (−0.557;-0.170)] and T3 vs. T1 [−0.234
(−0.426;-0.043)] were associated with lower endothelial
dysfunction (Table S3, model 2).
Fully adjusted continuous analyses showed that
10 nmol/L higher 25(OH)D3 was inversely associated
with lower endothelial dysfunction [−0.040 (−0.073;-
0.007)], but not low-grade inflammation [−0.019
(−0.049;0.011)]. In addition, comparing month-specific
T2 vs. T1 of 25(OH)D3 [−0.206 (−0.387;-0.024)], but
not T3 vs. T1 [−0.131 (−0.317;0.056)], 25(OH)D3, was
associated with lower low-grade inflammation and
month-specific 25(OH)D3 T3 vs. T1 [−0.215 (−0.416;-
0.015)], but not T2 vs. T1 [−0.149 (−0.343;0.046)], was
associated with lower endothelial dysfunction (Additional
file 1: Table S4, model 2).
We additionally adjusted the associations between
25(OH)D2 and 25(OH)D3 and microalbuminuria and
macroalbuminuria for the low-grade inflammation and
endothelial dysfunction scores and found that these as-
sociations did not materially change after adjustment for
low-grade inflammation and endothelial dysfunction
(Tables 2 and 3, model 3 and 4, respectively).
Discussion
The present study showed that in individuals with type 1
diabetes, higher circulating 25(OH)D2 as well as 25(OH)D3
were associated with a lower prevalence of macroalbumi-
nuria, but not with retinopathy and CVD. These associ-
ations were independent of age, sex, cardiovascular risk
factors and markers of low-grade inflammation and
endothelial dysfunction and did not differ between indi-
viduals with an eGFR below and above 90 mL/min.
The inverse associations between 25(OH)D2 and
25(OH)D3 and macroalbuminuria are in line with a pre-
vious prospective study in individuals with type 1 dia-
betes showing an independent and inverse association
between total 25(OH)D and microalbuminuria [11].
Our results extend these previously published results by
showing not only associations between 25(OH)D3 and
macroalbuminuria, but also similar associations between
25(OH)D2 and macroalbuminuria. Although vitamin D2
and D3 exhibit identical sets of biological responses
around the body, primarily through the same vitamin D
receptor mediated regulation of gene expression [28], re-
verse causation due to physical activity and influence of
seasonal variation were avoided in these analyses as circu-
lating 25(OH)D2 is not influenced by exposure to UV
light. These findings therefore support the association be-
tween vitamin D and albuminuria. Other cross-sectional
[12] and prospective [13] studies showed no associations
between total 25(OH)D [12] or 25(OH)D3 [13] and albu-
minuria in individuals with type 1 diabetes. Discrepancies
between the current findings and these previous findingsmay be explained by the lower numbers of albuminuria
cases in the previous than in the current study. Also, in
the study by Joergensen et al. [13], 25(OH)D3 was cate-
gorized and vitamin D deficiency was accordingly de-
fined as less than or equal to the lowest 10th percentile
of 25(OH)D3 concentration. However, seasonal vari-
ation was not adjusted for, which could have resulted in
misclassification of vitamin D deficient patients (i.e.,
possibly incorrectly classifying more patients as vitamin
D deficient in winter than in summer), thereby masking
potential associations. The single study that showed no
association between total 25(OH)D and albuminuria in
the general population [29] was also not adjusted for
seasonal variation, which may explain the lack of associ-
ation. In addition, independent and inverse associations
between total 25(OH)D and albuminuria have been
found in individuals with type 2 diabetes [30, 31] and in
the general population [32–34], which further support
our current findings in individuals with type 1 diabetes.
We found no independent associations between
25(OH)D2 and 25(OH)D3 and retinopathy. The signifi-
cant age- and sex-adjusted associations between both
25(OH)D2 and 25(OH)D3 and proliferative retinopathy
attenuated and became non-significant after adjustment
for other potential confounders (Table 2 and 3), in particu-
lar after adjustment for albuminuria status (data not
shown). Associations with albuminuria and retinopathy are
difficult to tease apart as these disease states strongly cor-
relate with each other. We therefore cannot exclude any
direct associations between both 25(OH)D2 and 25(OH)D3
and proliferative retinopathy. In a previous cross-sectional
study on individuals with type 1 diabetes, total 25(OH)D
has been associated with a lower prevalence of retinopathy
[12], a finding that could not be confirmed in another pro-
spective study however [13]. In individuals with type 2 dia-
betes results have also been conflicting as, similarly, both
inverse [31, 35] and no independent associations [35, 36]
have been described between total 25(OH)D and preva-
lence of retinopathy.
The present study did not show a continuous inverse as-
sociation between 25(OH)D2 and 25(OH)D3 and CVD.
Only individuals in the 2nd tertile, but not those in the 3rd
tertile of 25(OH)D2, compared to those in the 1
st tertile,
had a higher prevalence of CVD, which may reflect a
chance finding. In the general population, the inverse
association between 25(OH)D and CVD has been ex-
tensively described in meta-analyses [as summarized in
[37]], whereas no studies have been published on the asso-
ciations between total 25(OH)D, 25(OH)D2 or 25(OH)D3
and prevalent or incident CVD in type 1 diabetes. Larger,
prospective studies are needed to further examine the asso-
ciations between total 25(OH)D, 25(OH)D2 and 25(OH)D3
and the development of retinopathy and CVD in type 1
diabetes.
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Vitamin D receptors are present on a large variety of cell
types, including most immune cells and vascular endothe-
lial cells [38]. Overall, 1,25(OH)2D controls inflammatory
and immune responses, keeping them within physiological
boundaries [39]. In addition, vitamin D improves endothe-
lial cell function, regulating endothelial cell-dependent
vasodilation [5, 6]. Furthermore, the processes of (low-
grade) inflammation and endothelial dysfunction have
been associated with vascular complications in individuals
with type 1 diabetes [8, 9] and we therefore hypothesized
that the associations between 25(OH)D2 and 25(OH)D3
could be explained by these pathophysiological processes.
In the current study we indeed found associations be-
tween both 25(OH)D2 and 25(OH)D3 on the one hand
and markers of low-grade inflammation and endothelial
dysfunction on the other. However, associations between
25(OH)D2 and 25(OH)D3 and macroalbuminuria were in-
dependent of low-grade inflammation and endothelial dys-
function and may thus rather be mediated by processes
other than inflammation and endothelial dysfunction, such
as up-regulation of the RAAS [7, 10].
Conversion of 25(OH)D into its active form 1,25(OH)2D
is reduced in individuals with decreased kidney function
[1]. Therefore, eGFR may modify the associations between
25(OH)D2 and 25(OH)D3 on the one hand and micro-
vascular complications and CVD on the other. However,
we found no evidence to support this contention. This
may be explained by the low number of individuals with
impaired kidney function. Larger prospective studies that
include individuals with a larger variety in eGFR are
needed to fully address this issue. Similarly, parathyroid
hormone stimulates the kidneys to produce 1,25(OH)2D
[1] and may therefore also modify the association between
vitamin D and vascular complications. In addition, magne-
sium has an essential role in the synthesis and metabol-
ism of vitamin D and magnesium intake has already
been shown to modify the association between vitamin
D and risk of disease death in men [40]. Whether or not
parathyroid hormone and/or magnesium intake modify
the association between vitamin D and microvascular
complications and CVD in type 1 diabetes needs to be
further investigated.
Strengths and limitations
Strengths of the current study include the measurement
of both circulating 25(OH)D2 and 25(OH)D3. This is the
first observational cohort study in individuals with type
1 diabetes investigating associations between 25(OH)D2
and vascular complications. In addition, we extensively
controlled all associations for potential confounders in-
cluding season of examination. Furthermore, plasma
concentrations of vitamin D were comparable with
those previously reported in other cohort studies inindividuals with type 1 diabetes [11, 13], which indicates
good data integrity of our data.
A drawback of the current study is its cross-sectional de-
sign that does not allow conclusions on causality regarding
the associations between 25(OH)D2 and 25(OH)D3 and
microvascular complications of diabetes. Furthermore,
(cross-sectional) observational studies on vitamin D are
particularly susceptible to reverse causation as any disease
state is likely to reduce physical activity and thereby UV
light exposure. However, we could confirm the associations
between circulating 25(OH)D3 and albuminuria with simi-
lar associations between circulating 25(OH)D2 (which is
not directly influenced by exposure to UV light) and albu-
minuria. In addition, although we have extensively adjusted
for cardiovascular risk factors including physical activity,
and, in the case of 25(OH)D3 for seasonal variation, re-
sidual confounding may still have occurred. In the current
study we have no information on the use of vitamin D sup-
plements, which is expected to be a determinant of vitamin
D levels and may additionally represent health conscious-
ness and healthy behaviour, which may be related to vascu-
lar disease. Last, even though data on the active vitamin D
metabolite 1,25(OH)2D were not available for analyses,
25(OH)D concentrations may correlate better with clinical
outcomes than 1,25(OH)2D concentrations as most cardio-
vascular and inflammatory cells express 1αhydroxylase en-
abling local synthesis of 1,25(OH)2D. Measurement of
circulating 1,25(OH)2D does not include locally synthesized
1,25(OH)2D, whereas this local synthesis of 1,25(OH)2D
seems particularly important in the non-skeletal actions of
vitamin D [39, 41].
Conclusion
In individuals with type 1 diabetes, both higher 25(OH)D2
and 25(OH)D3 are associated with a lower prevalence of
macroalbuminuria, but not with retinopathy and CVD.
These associations are independent of season of examin-
ation and known cardiovascular risk factors such as phys-
ical inactivity, and independent of low-grade inflammation
and endothelial dysfunction. Larger and prospective stud-
ies are needed to further examine the associations between
25(OH)D2 and 25(OH)D3 and the development of micro-
vascular complications and CVD in type 1 diabetes.
Additional file
Additional file 1: Figure S1. Concentration of 25(OH)D2 (A) and
25(OH)D3 (B) according to latitude of the study centre. City, country code
and, between brackets, latitude of the study centre, and the number of
individuals per study centre are displayed on the x-axis. Boxes indicate
medians and interquartile ranges and whiskers represent the minimum
and maximum values. Table S1. Associations between 25-hydroxyvitamin
D2 tertiles and prevalent albuminuria, retinopathy and cardiovascular disease.
Table S2. Associations between month-specific 25-hydroxyvitamin D3 tertiles
and prevalent albuminuria, retinopathy and CVD. Table S3. Associations
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and endothelial dysfunction. Table S4. Associations between 25-
hydroxyvitamin D3 levels and markers of inflammation and endothelial
dysfunction.
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